JP2020531461A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531461A5 JP2020531461A5 JP2020508623A JP2020508623A JP2020531461A5 JP 2020531461 A5 JP2020531461 A5 JP 2020531461A5 JP 2020508623 A JP2020508623 A JP 2020508623A JP 2020508623 A JP2020508623 A JP 2020508623A JP 2020531461 A5 JP2020531461 A5 JP 2020531461A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- compound according
- composition
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims description 45
- 150000003839 salts Chemical class 0.000 claims description 32
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 239000001301 oxygen Substances 0.000 claims description 11
- 229910052717 sulfur Chemical group 0.000 claims description 11
- 239000011593 sulfur Chemical group 0.000 claims description 11
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 9
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 230000001404 mediated effect Effects 0.000 claims description 7
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 239000012472 biological sample Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 229940124597 therapeutic agent Drugs 0.000 claims description 4
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 3
- 229910052805 deuterium Inorganic materials 0.000 claims description 3
- 150000002431 hydrogen Chemical group 0.000 claims description 3
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 239000003981 vehicle Substances 0.000 claims description 2
- 125000001931 aliphatic group Chemical group 0.000 claims 4
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 1
- -1 benzo [1,3] dioxolyl Chemical group 0.000 description 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 229930195734 saturated hydrocarbon Natural products 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762546757P | 2017-08-17 | 2017-08-17 | |
| US62/546,757 | 2017-08-17 | ||
| US201862613141P | 2018-01-03 | 2018-01-03 | |
| US62/613,141 | 2018-01-03 | ||
| PCT/US2018/046957 WO2019036657A1 (en) | 2017-08-17 | 2018-08-17 | AHR INHIBITORS AND USES THEREOF |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020531461A JP2020531461A (ja) | 2020-11-05 |
| JP2020531461A5 true JP2020531461A5 (https=) | 2021-09-09 |
| JP7269917B2 JP7269917B2 (ja) | 2023-05-09 |
Family
ID=65360285
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020508623A Active JP7269917B2 (ja) | 2017-08-17 | 2018-08-17 | Ａｈｒ阻害剤およびその使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US10696650B2 (https=) |
| EP (1) | EP3668496A4 (https=) |
| JP (1) | JP7269917B2 (https=) |
| KR (1) | KR20200051646A (https=) |
| CN (1) | CN111163766A (https=) |
| AU (1) | AU2018319016B2 (https=) |
| BR (1) | BR112020003116A2 (https=) |
| CA (1) | CA3073051A1 (https=) |
| IL (1) | IL272649B2 (https=) |
| MX (1) | MX2020001793A (https=) |
| SG (1) | SG11202001310SA (https=) |
| WO (1) | WO2019036657A1 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018300150A1 (en) | 2017-07-11 | 2020-01-30 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| BR112020003116A2 (pt) | 2017-08-17 | 2020-08-04 | Ikena Oncology, Inc. | inibidores de ahr e usos dos mesmos |
| WO2020146682A1 (en) | 2019-01-10 | 2020-07-16 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| US12440481B2 (en) | 2019-01-10 | 2025-10-14 | Vertex Pharmaceuticals Incorporated | Esters and carbamates as modulators of sodium channels |
| JP7691974B2 (ja) * | 2019-07-25 | 2025-06-12 | キュラデブ ファーマ ピーブイティー． リミテッド | アセチル補酵素ａシンテターゼ短鎖２（ａｃｓｓ２）の小分子阻害剤 |
| WO2021080015A1 (en) * | 2019-10-24 | 2021-04-29 | Ono Pharmaceutical Co., Ltd. | Modulators of trek (twik related k+ channels) channel function |
| BR112022010924A2 (pt) | 2019-12-06 | 2022-09-06 | Vertex Pharma | Tetra-hidrofuranos substituídos como moduladores de canais de sódio |
| CA3167283A1 (en) | 2020-01-10 | 2021-07-15 | Ikena Oncology, Inc. | Ahr inhibitors and uses thereof |
| BR112022019517A2 (pt) | 2020-03-30 | 2022-12-06 | Hutchison Medipharma Ltd | Compostos de amida e usos dos mesmos |
| US12570638B2 (en) | 2020-05-20 | 2026-03-10 | Sail Biomedicines, Inc. | Fused imidazole derivatives as AHR antagonists |
| CN114181212B (zh) * | 2020-09-15 | 2023-06-06 | 山东轩竹医药科技有限公司 | 哒嗪酮类AhR抑制剂 |
| CN114835687B (zh) * | 2021-04-02 | 2023-09-05 | 北京华森英诺生物科技有限公司 | AhR抑制剂 |
| SMT202500481T1 (it) | 2021-06-04 | 2026-01-12 | Vertex Pharma | N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio |
| CN115572282B (zh) * | 2021-07-05 | 2024-07-09 | 华东理工大学 | 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用 |
| CN116135850A (zh) * | 2021-11-16 | 2023-05-19 | 深圳湾实验室 | 抗鼻咽癌的小分子抑制剂、化合物的制备方法及其应用 |
| CN119707643A (zh) * | 2023-09-28 | 2025-03-28 | 德明药泰生物技术（深圳）有限公司 | AhR调节剂及其应用 |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5403816A (en) * | 1990-10-25 | 1995-04-04 | Kumiai Chemical Industry Co., Ltd. | Picolinic acid derivative and herbicidal composition |
| AU710926B2 (en) | 1996-05-20 | 1999-09-30 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| ATE380176T1 (de) * | 1999-08-04 | 2007-12-15 | Icagen Inc | Benzanilide als öffner des kaliumkanals |
| US6608053B2 (en) | 2000-04-27 | 2003-08-19 | Yamanouchi Pharmaceutical Co., Ltd. | Fused heteroaryl derivatives |
| EP2168576A3 (en) | 2001-09-14 | 2010-05-26 | Shionogi & Co., Ltd. | Tricyclic compounds for treating dyslipidemia and arteriosclerotic diseases |
| CN1585751A (zh) * | 2001-10-25 | 2005-02-23 | 武田药品工业株式会社 | 喹啉化合物 |
| WO2003066055A1 (en) * | 2002-02-04 | 2003-08-14 | F. Hoffmann-La Roche Ag | Quinoline derivatives as npy antagonists |
| TWI380996B (zh) | 2004-09-17 | 2013-01-01 | Hoffmann La Roche | 抗ｏｘ４０ｌ抗體 |
| JP2008520749A (ja) | 2004-11-23 | 2008-06-19 | レディ ユーエス セラピューティックス， インコーポレイテッド | 新規二環式ヘテロ環化合物、その調製のためのプロセス、およびその新規二環式ヘテロ環化合物を含む組成物 |
| PT2343320T (pt) | 2005-03-25 | 2018-01-23 | Gitr Inc | Anticorpos anti-gitr e as suas utilizações |
| PL1879573T3 (pl) | 2005-05-10 | 2013-05-31 | Incyte Holdings Corp | Modulatory 2,3-dioksygenazy indoloaminy i sposoby ich zastosowania |
| PT1907424E (pt) | 2005-07-01 | 2015-10-09 | Squibb & Sons Llc | Anticorpos monoclonais humanos para o ligando 1 de morte programada (pd-l1) |
| US8450351B2 (en) | 2005-12-20 | 2013-05-28 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| US20070254926A1 (en) * | 2006-01-31 | 2007-11-01 | Jun Jiang | Pyridylphenyl compounds for inflammation and immune-related uses |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| WO2008058126A2 (en) | 2006-11-06 | 2008-05-15 | Supergen, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
| CA2684105C (en) * | 2007-05-03 | 2011-09-06 | Pfizer Limited | Pyridine derivatives |
| ES2637999T3 (es) * | 2007-05-17 | 2017-10-18 | Helperby Therapeutics Limited | Uso de compuestos de 4-(pirrolidin-1-il)quinolina para eliminar microorganismos clínicamente latentes |
| CL2008001626A1 (es) * | 2007-06-05 | 2009-06-05 | Takeda Pharmaceuticals Co | Compuestos derivados de heterociclos fusionados, agente farmaceutico que los comprende y su uso en la profilaxis y tratamiento del cancer. |
| US8591886B2 (en) | 2007-07-12 | 2013-11-26 | Gitr, Inc. | Combination therapies employing GITR binding molecules |
| EP2044949A1 (en) | 2007-10-05 | 2009-04-08 | Immutep | Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response |
| US10047066B2 (en) | 2007-11-30 | 2018-08-14 | Newlink Genetics Corporation | IDO inhibitors |
| ES2586459T3 (es) | 2008-05-01 | 2016-10-14 | Glaxosmithkline Llc | Quinolinas y análogos relacionados como moduladores de sirtuina |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| KR101790802B1 (ko) | 2009-09-03 | 2017-10-27 | 머크 샤프 앤드 돔 코포레이션 | 항-ｇｉｔｒ 항체 |
| EP2493862B1 (en) | 2009-10-28 | 2016-10-05 | Newlink Genetics Corporation | Imidazole derivatives as ido inhibitors |
| ES2722300T3 (es) | 2009-12-10 | 2019-08-09 | Hoffmann La Roche | Anticuerpos que se unen preferentemente al dominio extracelular 4 de CSF1R y su uso |
| EP2542256B1 (en) | 2010-03-04 | 2019-05-22 | MacroGenics, Inc. | Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof |
| US9169323B2 (en) | 2010-03-05 | 2015-10-27 | Hoffmann-La Roche Inc. | Antibodies against human CSF-1R |
| JP5989547B2 (ja) | 2010-03-05 | 2016-09-07 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | ヒトｃｓｆ−１ｒに対する抗体及びその使用 |
| HRP20190047T1 (hr) | 2010-05-04 | 2019-02-22 | Five Prime Therapeutics, Inc. | Protutijela koja se vežu na csf1r |
| MX337040B (es) | 2010-09-09 | 2016-02-09 | Pfizer | Moleculas de union a 4-1bb. |
| US8410107B2 (en) * | 2010-10-15 | 2013-04-02 | Hoffmann-La Roche Inc. | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| NO2694640T3 (https=) | 2011-04-15 | 2018-03-17 | ||
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| US9593062B2 (en) | 2011-09-07 | 2017-03-14 | Deutschland Krebsforschungszentrum | Means and methods for treating and/or preventing natural AHR ligand-dependent cancer |
| ES2882807T3 (es) * | 2011-09-16 | 2021-12-02 | Novartis Ag | Heterociclil carboxamidas N-sustituidas |
| WO2013059677A1 (en) * | 2011-10-19 | 2013-04-25 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| RU2658603C2 (ru) | 2011-12-15 | 2018-06-21 | Ф.Хоффманн-Ля Рош Аг | Антитела против человеческого csf-1r и их применения |
| KR20140127855A (ko) | 2012-02-06 | 2014-11-04 | 제넨테크, 인크. | Csf1r 억제제를 사용하는 조성물 및 방법 |
| AR090263A1 (es) | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
| RU2670743C9 (ru) | 2012-05-11 | 2018-12-19 | Файв Прайм Терапьютикс, Инк. | Способы лечения состояний антителами, которые связывают рецептор колониестимулирующего фактора 1 (csf1r) |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| CN107759690A (zh) | 2012-08-31 | 2018-03-06 | 戊瑞治疗有限公司 | 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法 |
| WO2014138485A1 (en) | 2013-03-08 | 2014-09-12 | Irm Llc | Ex vivo production of platelets from hematopoietic stem cells and the product thereof |
| BR112017014269A2 (pt) * | 2014-12-31 | 2018-03-27 | Anthrogenesis Corp | células exterminadoras naturais e usos das mesmas |
| US11221329B2 (en) * | 2015-10-30 | 2022-01-11 | Lieber Institute, Inc. | Treatment of neurological and neurodevelopmental diseases and disorders associated with aberrant ion channel expression and activity |
| WO2018085348A1 (en) * | 2016-11-03 | 2018-05-11 | Actavalon, Inc. | Substituted quinolines and methods for treating cancer |
| TW201841916A (zh) | 2017-04-12 | 2018-12-01 | 美商麥珍塔治療學股份有限公司 | 芳香烴受體拮抗劑及其用途 |
| MX2019012431A (es) | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
| US11548867B2 (en) | 2017-07-19 | 2023-01-10 | Idea Ya Biosciences, Inc. | Amido compounds as AhR modulators |
| BR112020003116A2 (pt) | 2017-08-17 | 2020-08-04 | Ikena Oncology, Inc. | inibidores de ahr e usos dos mesmos |
| US20190314407A1 (en) | 2017-10-31 | 2019-10-17 | Magenta Therapeutics Inc. | Compositions and methods for the expansion of hematopoietic stem and progenitor cells |
| SG11202003807RA (en) | 2017-11-03 | 2020-05-28 | Univ Montreal | Compounds and use thereof in the expansion of stem cells and/or progenitor cells |
| EP3713926B1 (en) | 2017-11-21 | 2023-06-07 | Bayer Aktiengesellschaft | 2-hetarylpyrimidine-4-carboxamides as aryl hydrocarbon receptor anatgonists |
| CA3082857A1 (en) | 2017-11-21 | 2019-05-31 | Bayer Aktiengesellschaft | 3-oxo-6-heteroaryl-2-phenyl-2,3-dihydropyridazine-4-carboxamides |
| CA3082856A1 (en) | 2017-11-21 | 2019-05-31 | Bayer Aktiengesellschaft | Sulphur substituted 3-oxo-2,3-dihydropyridazine-4-carboxamides |
| EP3713923B1 (en) | 2017-11-21 | 2021-12-01 | Bayer Aktiengesellschaft | 2-phenylpyrimidine-4-carboxamides as ahr inhibitors |
-
2018
- 2018-08-17 BR BR112020003116-0A patent/BR112020003116A2/pt not_active IP Right Cessation
- 2018-08-17 JP JP2020508623A patent/JP7269917B2/ja active Active
- 2018-08-17 AU AU2018319016A patent/AU2018319016B2/en not_active Ceased
- 2018-08-17 SG SG11202001310SA patent/SG11202001310SA/en unknown
- 2018-08-17 EP EP18845707.1A patent/EP3668496A4/en not_active Withdrawn
- 2018-08-17 CN CN201880063670.4A patent/CN111163766A/zh active Pending
- 2018-08-17 CA CA3073051A patent/CA3073051A1/en active Pending
- 2018-08-17 KR KR1020207007714A patent/KR20200051646A/ko not_active Abandoned
- 2018-08-17 US US16/104,747 patent/US10696650B2/en active Active
- 2018-08-17 MX MX2020001793A patent/MX2020001793A/es unknown
- 2018-08-17 WO PCT/US2018/046957 patent/WO2019036657A1/en not_active Ceased
-
2020
- 2020-02-13 IL IL272649A patent/IL272649B2/en unknown
- 2020-06-02 US US16/890,196 patent/US11555026B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020531461A5 (https=) | ||
| JP2020517734A5 (https=) | ||
| JP7710356B2 (ja) | ５，１０－メチレン－（６ｒ）－テトラヒドロ葉酸のヘミ硫酸塩 | |
| JP2022502476A5 (https=) | ||
| ES2975263T3 (es) | Formas cristalinas de un compuesto triazolopirimidínico | |
| FI74019C (fi) | Foerfarande foer framstaellning av 7 -acylamino-3-substitueradmetyl-3-cefem-4-karboxylsyraderivat. | |
| BR112019014756B1 (pt) | Composto inibidor de ask1 e composição farmacêutica que o compreende | |
| WO2007050963A1 (en) | Novel ido inhibitors and methods of use thereof | |
| BR112012023649B1 (pt) | Método para produção de cristais de forma ii de monoidrato de n1 -(5-cloropiridin-2-il)-n2 -((1s,2r,4s)-4-[(dimetilamino) carbonil]-2-{[(5-metil-4,5,6,7-tetrahidrotiazol[5,4-c]piridin-2-il) carbonil] amino}ciclohexil)etanodiamida p-toluenossulfonato | |
| ES2577391T3 (es) | Polimorfos de un antagonista del receptor mglur5 | |
| Ashok et al. | Synthesis and anti-leishmanial evaluation of 1-phenyl-2, 3, 4, 9-tetrahydro-1H-β-carboline derivatives against Leishmania infantum | |
| ES2699452T3 (es) | Nuevo derivado de triazina | |
| CN104356090B (zh) | 一种蓝萼甲素的噻唑衍生物及其制备方法和应用 | |
| JP6929299B2 (ja) | インドール誘導体を含む医薬組成物、その調製方法及びその使用 | |
| TW201636340A (zh) | 化合物 | |
| IL184781A (en) | CRYSTALLINE 1H-IMIDAZO[4,5-b]PYRIDIN-5-AMINE, 7-[5-[(CYCLOHEXYLMETHYLAMINO)-METHYL]-1H-INDOL-2-YL]-2-METHYL, SULFATE (1:1), TRIHYDRATE AND ITS PHARMACEUTICAL USES | |
| CN112334470A (zh) | 5-甲基-(6s)-四氢叶酸和氨基酸乙酯的结晶盐 | |
| WO2025054386A1 (en) | Cdk2 inhibitors and uses thereof | |
| Lungu et al. | Phenacyl 3-methylpiperidinyl carbodithioates as building blocks for 1, 3-dithiolium derivatives | |
| BR112017010938B1 (pt) | Compostos hidrossolúveis derivados do benzimidazol, composição farmacêutica e uso da composição farmacêutica | |
| SU795481A3 (ru) | Способ получени производныхцЕфАлОСпОРиНА или иХ СОлЕй | |
| JP2024543882A (ja) | 寄生性原生動物感染症に有用なピラジン化合物 | |
| BR122026000464A2 (pt) | Formas cristalinas de um inibidor de fosfoinositídeo 3-quinase (pi3k), seus usos, sais, composições e processos de preparação | |
| KR830000130B1 (ko) | 메르캅토 이미다졸 유도체의 제조방법 | |
| CN105745203A (zh) | 新三嗪衍生物 |